Furosemide is a diuretic which is an anthranilic acid derivative.
Parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations.
Furosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired.
Furosemide is indicated as adjunctive therapy in acute pulmonary edema. The intravenous administration of furosemide is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema.
If gastrointestinal absorption is impaired or oral medication is not practical for any reason, furosemide is indicated by the intravenous or intramuscular route. Parenteral use should be replaced with oral furosemide as soon as practical.
Published Studies Related to Furosemide Injection (Furosemide)
The adjunctive effect of nebulized furosemide in COPD exacerbation: a randomized
controlled clinical trial. 
department... CONCLUSIONS: Nebulized furosemide benefits patients with COPD exacerbation.
Troponin I release after intravenous treatment with high furosemide doses plus
hypertonic saline solution in decompensated heart failure trial (Tra-HSS-Fur). 
with ADHF... CONCLUSIONS: These data demonstrate that intravenous high doses of furosemide do
Furosemide for packed red cell transfusion in preterm infants: a randomized controlled trial. [2011.12]
OBJECTIVE: To assess the effect of furosemide administered with packed red blood cell transfusion on cardiopulmonary variables of hemodynamically stable, electively transfused preterm infants beyond the first week of life... CONCLUSIONS: Routine furosemide in electively transfused preterm infants confers minimal clinical benefits. Prevention of a clinically insignificant FiO(2) rise needs to be balanced against potential adverse effects. Copyright (c) 2011 Mosby, Inc. All rights reserved.
Randomized, open-label, 5-way crossover study to evaluate the pharmacokinetic/pharmacodynamic interaction between furosemide and the non-steroidal anti-inflammatory drugs diclofenac and ibuprofen in healthy volunteers. [2011.08]
OBJECTIVE: Nonsteroidal anti-inflammatory drugs (NSAIDs) can induce renal complications in patients taking loop diuretics. This study investigated the pharmacokinetic/pharmacodynamic effects and safety profile of orally administered diclofenac sodium, ibuprofen and diclofenac epolamine topical patch (DETP) on furosemide in healthy adult subjects... CONCLUSIONS: Pharmacodynamic effects were seen with oral diclofenac (urine output) and ibuprofen (urine sodium excretion). Furosemide also affected plasma and urine pharmacokinetic profiles. Pharmacologic effects of DETP on furosemide were not observed under these conditions. Additional research is warranted to delineate the potential interactions of other NSAIDs with furosemide and other loop diuretics.
Randomized placebo controlled trial of furosemide on subjective perception of dyspnoea in patients with pulmonary oedema because of hypertensive crisis. [2011.06]
CONCLUSIONS: The subjective perception of dyspnoea in patients with hypertensive pulmonary oedema was not influenced by the application of a loop-diuretic. Therefore, additional furosemide therapy needs to be scrutinized in the therapy of these patients. (c) 2010 The Authors. European Journal of Clinical Investigation (c) 2010 Stichting European Society for Clinical Investigation Journal Foundation.
Clinical Trials Related to Furosemide Injection (Furosemide)
Magnetic Marker Monitoring of Furosemide-containing Gastroretentive Formulation in Healthy Male Subjects (Fasting and Fed Conditions) [Completed]
Furosemide is a diuretic drug, used in the treatment of oedematous states associated with
cardiac, renal, and hepatic disorder, and may be effective in patients unresponsive to
thiazide diuretics. Furosemide is also used in the treatment of hypertension.
Absorption of furosemide from the gastrointestinal tract is fairly rapid; bioavailability is
60-70%, but variable and not predictable, with large intra- and inter-individual
variability, and are influenced by dosage form, underlying diseases, and by the presence of
food after oral administration. Data from animal model show that furosemide administered
into the stomach is more rapidly absorbed than if is administered into the small intestine.
To increase the residency of furosemide in the stomach after oral administration, a
gastroretentive dosage form (GRDF) of furosemide has been developed. In the current study,
the new formulation (30mg furosemide coated tablet) will be tested in healthy male
subjects. Absorption will be characterised by an effective and safe imaging technique -
Magnetic Marker Monitoring (MMM), based on Fe3O4 added to the drug product to generate
magnetic signal that can be used for up to 12 h after furosemide administration to localize
the medication in the gastrointestinal tract. Fe3O4 is frequently used as colouring pigment
in medicinal products. It does not exhibit own pharmacodynamic activity and is considered as
an inactive ingredient.
In the current study, GRDF formulation of furosemide will be evaluated for: gastric
residence as well as pharmacokinetic and pharmacodynamic characteristics under fasting and
fed conditions. As part of the study, the subjects will be hospitalized for 1 day during
each drug administration. The duration of the stay will depend on the intestinal behaviour
of the investigational product.
Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD) [Not yet recruiting]
This study will describe the safety of furosemide in premature infants at risk of
bronchopulmonary dysplasia and determine the preliminary effectiveness and pharmacokinetics
(PK) of furosemide.
Pharmacokinetic Profile and Pharmacodynamic Characteristics of a Furosemide High Dosage Formulation in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis [Completed]
- To determine the absolute bioavailability of furosemide 500 mg (Lasix® Special) oral
formulation in patients with chronic renal failure undergoing peritoneal dialysis.
- To determine the pharmacokinetic profiles of furosemide 500 mg (Lasix® Special) oral
formulation and 250 mg IV formulation
- To compare the pharmacodynamic characteristics of furosemide 500 mg (Lasix® Special)
oral formulation and 250 mg IV formulation
Furosemide Stress Test as a Predictor of Tubular Function in Chronic Kidney Disease [Recruiting]
In kidney diseases, tubule-interstitium has become much more relevant, as formerly only the
glomerulus was considered to have the main importance. Kidney's tubular atrophy and
interstitital fibrosis is now recognized as long term prognostic value. We aim to evaluate
the function of the kidney's tubule-interstitium through furosemide excretion after
intravenous administration of this drug, and correlate the rate of excretion of furosemide
with interstitial fibrosis findings in scheduled kidney biopsy for patients with chronic
The Use of Furosemide in Patients on Dialysis [Recruiting]
Patients often begin dialysis taking diuretics (stimulate the kidney to excrete salt and
water). Once on dialysis, these drugs are often continued. Whether these drugs are still
needed, or even effective is often unclear. This study,by evaluating the composition of the
patients' urine when off the drug, will predict which patients should benefit from the drug.
By comparing their 24 hour volume both off and on the drug, the impact of the drug will be
established. The results will allow the prediction of which patients, in the future, should
take the drug. The hypothesis is: Among dialysis recipients, evaluation of the random urine
sodium concentration will help predict the likelihood of a positive response to Furosemide,
as manifested by an increased urine volume and sodium excretion.